REVIEW ARTICLE

Retinoblastoma in Mexico: Part I. A review of general knowledge of the disease, diagnosis, and management

Van C. Lansingh\textsuperscript{a,b,c}, Kristen A. Eckert\textsuperscript{d}, Barrett G. Haik\textsuperscript{c}, Blanca X. Phillipps\textsuperscript{c}, Vanessa Bosch-Canto\textsuperscript{e}, Carlos Leal-Leal\textsuperscript{e}, Marco A. Ramírez-Ortiz\textsuperscript{f,*}

\textsuperscript{a} Instituto Mexicano de Oftalmología, Querétaro, Querétaro, Mexico
\textsuperscript{b} Help Me See, New York, NY, USA
\textsuperscript{c} Department of Ophthalmology, Hamilton Eye Institute, The University of Tennessee Health Science Center, Memphis, TN, USA
\textsuperscript{d} Independent Public Health Consultant, Tapachula, Chiapas, Mexico
\textsuperscript{e} Instituto Nacional de Pediatría, Mexico City, Mexico
\textsuperscript{f} Department of Ophthalmology, Hospital Infantil de México Federico Gómez, Mexico City, Mexico

Received 27 May 2015; accepted 4 September 2015

KEYWORDS
Retinoblastoma;
Epidemiology;
Early cancer detection;
Disease management

Abstract This is the first of a two-part review that aims to report the current knowledge of retinoblastoma (Rb) and its implications in Mexico (including the authors' experience at the leading Rb centers), identify the gaps in practice, and propose solutions to improve diagnosis, treatment, and patient uptake. In this first part, general knowledge of Rb diagnosis and management is summarized with a focus on the latest advances in chemotherapy. A general review of peer-reviewed literature of Rb was conducted on PubMed. Key findings were summarized.

Provided there is early detection and referral of patients followed by appropriate conservative management, Rb is curable. In developed countries, the primary treatment outcome is ocular salvage with sight preservation. Advanced chemotherapeutic options such as intra-arterial and intravitreal chemotherapy can now save even the most advanced tumors.

Advances in Rb therapy are generally limited to developed countries. The implications in Mexico, of the findings from this review will be discussed in Part 2, which will be a comprehensive situational analysis of the state of Rb programming in Mexico including a review of current demographic data available from hospitals that have Rb programs or treat Rb.

© 2015 Hospital Infantil de México Federico Gómez. Published by Masson Doyma México S.A. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction

Retinoblastoma (Rb) is the most common primary malignancy in children, most frequently occurring in children <5 years of age, with an annual incidence ranging worldwide from 36/1,000,000 live births to 67/1,000,000 live births.\textsuperscript{1,5} Accurate incident rates can be difficult to estimate, especially in developing countries that lack a national Rb registry. In fact, a recent study from the Asia-Pacific region would suggest that cases of Rb are being underreported by >50%.\textsuperscript{6}

A curable cancer, Rb survival rates in the developed world range from 90-95%, mainly due to early diagnosis of the disease and to the advances made over the past few decades in conservative treatment.\textsuperscript{5,7,8} However, survival rates are significantly lower in developing countries; in Africa, they are estimated as low as 20%, and >3,000 annual childhood deaths are attributed worldwide to Rb.\textsuperscript{8,10} The poorer outcomes in developing countries have been associated with late diagnosis and treatment, lower educational levels of the mother, lack of access to health services, and treatment abandonment by families of the patient.\textsuperscript{11,12}

This article is the first part of a two-part review with the objective to report the current situation of Rb in Mexico, including the authors’ own experience at the country’s leading Rb centers and a review of currently available demographic data of patients with Rb at hospitals with Rb programs or that treat for Rb. We will also identify gaps in practice and propose solutions to improve diagnosis, provide adequate treatment, and improve patient uptake. The situational analysis of Rb in Mexico will be performed within the context of the general universal knowledge of Rb diagnosis and management. In this first part, we will summarize the general knowledge of Rb diagnosis and management including the latest advances in chemotherapy options.

2. Methods

A general, unstructured literature search was performed using PubMed to search for peer-reviewed journal articles on the current knowledge of Rb diagnosis and management. No specific search parameters were applied. Key findings from the literature are summarized.

3. Results

3.1. Pathology, diagnosis, and clinical characteristics

There are two forms of Rb, hereditary or non-hereditary, both of which develop from the mutation of the Rb (RB1) gene.\textsuperscript{14–16} In the non-hereditary form, inactivation of the RB1 gene alleles causes a defect of the pRB protein, resulting in unilateral tumors.\textsuperscript{14,15} The presence of tumors in both eyes can occur with heritable Rb.\textsuperscript{16} A parent carrier of a single mutant allele of the RB1 gene is a hereditary risk factor that predisposes the child to the loss of the second copy by 1,000 times the rate of spontaneous mutation.\textsuperscript{14} There is a 50% chance that the parent passes the mutation to their child, who then has a 90% chance of developing Rb.\textsuperscript{17} The hereditary form increases the risk of patient susceptibility to other cancers and requires long-term follow-up, genetic counseling, and monitoring for second cancers.\textsuperscript{15} The genetic nature of Rb, therefore, is very important in predicting the risk of cancer and guiding treatment.

It has been recently discovered that amplification of the MYCN gene (found only in tumor cells) results in another genetic form of the disease.\textsuperscript{15,14} Patients with this form are not at risk for second cancers. However, their tumors tend to be larger, invasive, and aggressive; thus, ocular salvage risks
high morbidity and treatment failure. For now, enucleation is the most optimal treatment for these cases.15,18 Rb is generally diagnosed based on clinical characteristics at presentation that are found using imaging modalities.9 Benign lesions and end-stage conditions can mimic the disease and lead to unnecessary treatment; thus, careful and accurate identification and staging of the disease is key to guiding patient-based treatment.19-22

Although there is no universal staging system that considers all risk factors of the disease in the detection process, the International Classification for Intraocular Retinoblastoma (ICIR) has been validated to more accurately predict treatment outcomes.20-23 The ICIR stages Rb in five groups, A through E, with Group A representing more easily treatable eyes of very low risk, and risk progression and complexity of treatment increasing through Group E, the very high-risk eyes.20 The cancer characteristics of each ICIR group are summarized in Table 1 with the recommended treatments and their associated complications and risks. Group A eyes have small tumors ≤3 mm in size, lack vitreous/subretinal seeding, and are located ≥3 mm from the foveola and ≥1.5 mm from the optic nerve. Groups B, C, and D eyes have tumors of any size or location; vitreous/subretinal seeding becomes present in Group C eyes, whereas Group D eyes have massive seeds and retinal attachment can occur. Groups A, B, and C can be managed conservatively by chemotherapy with the objective to salvage the eye, whereas Group D requires intra-arterial chemotherapy (IAC) or intravitreal chemotherapy (IVC). For Group E tumors where co-morbidities such as irreversible glaucoma are present, the tumor approaches the lens of the eye, and massive intraocular hemorrhage is present. The standard of care is enucleation, although IAC may also be used.

Histopathologic evidence of high-risk, metastatic Rb has been found in 17% of Group D and 24% of Group E eyes, indicating that even after enucleation, adjunctive chemotherapy may still be necessary to manage the spread of cancer to other parts of the body.39

3.2. Rb treatment modalities: conservative management

Over the past few decades, advances in genetic technologies, improved staging and classification, and a multidisciplinary team approach to conservative management of Rb have transformed the treatment primary outcome to ocular salvage and preservation of vision in Group A, B, and C cases, in addition to many advanced cases (Group D).5,7,13,40-46 Systemic chemotherapy is commonly used to treat the tumor with ocular salvage rates of 30-90%.45,46 Other conservative modalities are focal consolidation and transpupillary thermotherapy (TTT), laser photoocoagulation (LP), cryotherapy (CT), plaque brachytherapy, and local chemotherapy delivered by subconjunctival, subtenon, intravitreal, or intra-arterial routes (Table 1). Combined conservative treatment has been proven to be more effective, in which chemotherapy is initially applied to reduce the tumor size so that local therapies such as CT or TTT can then eliminate the disease.9 Choosing which modalities to use depends on the patient and tumor stage, and the complications and risks vary (Table 1).

In the more advanced cases (Groups E and D), external beam radiotherapy (EBRT) and enucleation are applied. A 10-year retrospective review of the use of systemic chemotherapy in Sweden at the sole national Rb referral center found that 35% of all eyes required enucleation and EBRT, as well as 91% of eyes with Group C/D tumors.40 Enucleation is the standard of care for when sight preservation is very unlikely or where the tumor may spread to the optic nerve, choroid, or orbit.5,38

3.3. Advanced therapy for Rb: IAC and IVC

Vitreous seeding is the main barrier to successful conservative treatment of advanced Rb.48 Chemoresistant vitreous seeds form in tumor cells after the cells proliferate in the avascular vitreous environment. IAC and IVC are emerging primary therapies to prevent EBRT or enucleation for advanced cases with vitreous seeding in developed countries.48-52 IAC with melphalan/topotecan is now a first-line treatment for Group C and D eyes.52,53 The goal is to achieve tumor regression with minimal local and systemic toxicities. Evidence is, however, limited on the safety and efficacy of IAC.54

Multiple preclinical and clinical studies in Argentina have evaluated the safety and efficacy of intra-arterial melphalan and topotecan.55-57 Schaiquevich et al. reported the first pharmacokinetic study of melphalan after superselective ophthalmic artery infusion (SSOAI) in children with Rb, in addition to evaluating and validating the effect in pigs.55 The authors evaluated the cytotoxicity of melphalan administered with and without topotecan in Rb cell lines of 17 patients and five pigs. The authors previously found that topotecan permeated more efficiently by 5- to 10-fold into the vitreous cavity of the same animal model than melphalan.58 Plasma concentration vs. time profile was similar when corrected by weight in both patients and the animal model.55 There was thus a low systemic exposure to melphalan in the patients. At 4 h post-SSOAI, topotecan concentrations in the vitreous of the pigs remained greater than its IC50; a similar effect was not found in pigs treated solely with melphalan, which appears to permeate inefficiently through the blood-retinal barrier to the vitreous.55,58 The authors suggested that a SSOAI combined regimen of melphalan and topotecan might be a safer alternative to increasing melphalan dosage.55 These findings were further confirmed by the authors in a single-center, prospective study that evaluated the safety and efficacy of combined melphalan (3-6 mg) and topotecan (0.5-1) for 66 cycles SSOAI in 26 patients (27 eyes) with Rb.46 This regimen was administered as primary therapy in five eyes, which all responded favorably and were preserved. In 22 eyes with relapsed or resistant tumors, 16 responded well, whereas three were enucleated after a median of 8 months (range: 7.9-9.1 months). Grade III and IV neutropenia had respective incidence rates of 10.6% and 1.5%, without any fever. Blood transfusion was not required, which further demonstrated a hematologic toxicity profile comparable with single-agent melphalan.56

The same authors next evaluated the effect of SSOAI compared to a historical cohort of sequential pericentral and systemic chemotherapy on ocular salvage for 18 patient eyes in 15 consecutive patients that failed chemoreduction and EBRT in a pilot program.57 Three eyes were treated with SSOAI using melphalan alone, four eyes were treated with combined topotecan, carboplatin, and melphalan, and one
eye was treated with topotecan and carboplatin without melphalan; all eyes received a median of four cycles of SSOAI (range: 2-9). Periocular topotecan or carboplatin was administered, respectively, to nine and one eyes in a median of two cycles (range: 1-3) followed by intravenous topotecan and cyclophosphamide. All patients survived their treatment without extraocular dissemination or second malignancy and with similar, mild ocular toxicity. Enucleation-free eye survival at 12 months had a probability of 0.87 (95% confidence interval [CI]: 0.42-0.97) for the SSOAI group com-

| ICIR Group \(^{20} \) | Characteristics \(^{20} \) | Treatment Recommended \(^{24} \) | Complications/Risks |
|---|---|---|---|
| A (very low risk) | • Tumors ≤3 mm in size  
• Tumors found ≥3 mm from the foveola and ≤1.5 mm from the optic nerve  
• No vitreous/subretinal seeding | Focal therapy including:  
• Transpupillary thermotherapy (TTT)  
• Cryotherapy (CT)  
• Laser photocoagulation (LP) | Complications vary for each therapy:  
• TTT: Focal iris atrophy and peripheral focal lens opacity \(^{25} \)  
• CT: lid edema, transient conjunctival edema, and transient localized serous retinal detachments \(^{26,27} \)  
• LP: retinal detachment, vascular occlusions, retinal traction, and pre-retinal fibrosis \(^{28-30} \) |
| B (low risk) | • Tumors of any size/location  
• No vitreous/subretinal seeding  
• Subretinal fluid cuff extending ≤5 mm from the tumor base | Systemic chemotherapy (VEC)  
• Focal therapy with chemotherapy cycles  
• Plaque radiotherapy (PRT) |  
| C (moderate risk) | • Discrete tumors of any size/location  
• Focal vitreous/subretinal seeding present that extends ≤3 mm from tumor base  
• ≤1 quadrant of subretinal fluid may be present | Systemic chemotherapy (VEC)  
• Focal therapy  
• Subtenon carboplatin (STC) | PRT: dryness of the eye, irritation, madarosis, cataract, scleral necrosis, radiation retinopathy or papillopathy, optic neuropathy, and strabismus \(^{31-34} \)  
• STC: optic nerve ischemic necrosis/atrophy, reduced ocular motility, moderate loss of orbital volume, and pseudopreseptal cellulitis \(^{35-37} \)  
• EBRT: vision loss, cataracts, irritation \(^{3} \) |
| D (high risk) | • Diffuse vitreous subretinal seeding and/or massive nondiscrete endophytic/exophytic disease present  
• ≥1 quadrant of retinal detachment | Systemic chemotherapy (VEC)  
• Focal therapy  
• STC  
• EBRT |  
| E (very high risk) | One or more of the following present in eyes:  
• Irreversible neovascular glaucoma  
• Massive intraocular hemorrhage  
• Aseptic orbital cellulitis  
• Phthisis/pre-phthisis tumor anterior to anterior vitreous face  
• Tumor touches the lens  
• Diffuse infiltrating retinoblastoma | Systemic chemotherapy (VEC)  
• Enucleation \(^{38} \) |  

VEC, vincristine, etoposide, carboplatin via six cycles given every 28 days; EBRT, external beam radiotherapy.
pared to 0.1 (95% CI: 0.06–0.35) for the periocular group (p < 0.01). Systemic toxicity was low for both groups; however, patients treated with intravenous chemotherapy had five episodes of grade 4 neutropenia, three of which required hospitalizations, whereas no such complications occurred in the SSOAI group. Thus, SSOAI was significantly superior and less toxic when compared to periocular and systemic chemotherapy in eyes with relapsed Rb.67

Outside of Argentina, a systematic review on the complication of IAC found that significant complications were uncommon and supports that the risk may be minimized through careful injection and limiting the dosage.68 A more recent retrospective interventional case series found that IAC was an effective primary and secondary treatment with a mean globe salvage rate for Group A-D eyes of 95% and a salvage rate of 36% for Group E eyes.69 The authors observed that treatment failed in eyes with extensive recurrent vitreous seeds. It should be taken into consideration that vascular toxic effects in the eye and orbit have recently been demonstrated in primates after IAC.70 Further research is necessary to confirm and validate that IAC is safe and effective, including a multi-center, prospective trial that would analyze the globe salvage benefits of IAC,48,59 but IAC appears to be appropriate treatment for a select patient population with Rb.62

An alternative therapy for tumors with vitreous seeds, IVC is a regimen of high-dosage chemotherapy and has an ocular salvage rate of 71–95% and a vision salvage rate of 96% (among patients with ocular salvage).61 The presence of vitreous seeding reduces the prognosis of tumor control. IVC with melphalan offers an option for these patients. It has to be done by an experienced group because of eligibility criteria and the high risk of tumor spread, in addition to the need for hospitalizations, whereas no such complications occurred in the SSOAI group. Thus, SSOAI was significantly superior and less toxic when compared to periocular and systemic chemotherapy in eyes with relapsed Rb.67

For example, other recent animal and clinical studies in Argentina have evaluated the safety and efficacy of IVC using topotecan66,67 and digoxin68 with promising results. As an alternative to melphalan, intravitreal injections of 5 µg of topotecan were administered to rabbits.56 For up to 48 h following administration, high concentrations of topotecan were observed in the vitreous humor, with the respective median maximum vitreous, aqueous, and plasma total topotecan concentrations being 5.3, 0.68, and 0.21 µg/ml. There was evidence of low systemic exposure with total topotecan exposure in the vitreous 50 times greater than the total systemic exposure. Next, the authors tested two different doses of 5 µg vs. 0.5 µg of intravitreal topotecan administered to rabbits in 4 weekly injections to see if a lower dose had a potential therapeutic effect.64 Eyes injected with either dose demonstrated no significant differences in electroretinography wave amplitudes and implicit times in comparison in compared with a control group (p > 0.05). There was no significant histologic damage of the retinas in rabbits treated with topotecan and no other complications observed. Although 4 weekly intravitreal injections of 5 µg or 0.5 µg of topotecan were safe in the rabbits’ eye, lactone topotecan vitreous concentrations in rabbits injected with only 0.5 µg were potentially active only after 5 h.66 The same authors reviewed 42 animal and clinical studies for the ocular pharmacology and antitumor activity of topotecan and camptothecins for Rb treatment via different administrative methods.97 Topotecan administered alone or combination via IAC and IVC was effective with minimal ocular toxicity. However, its clinical role and optimal dose and route of administration remain to be determined.97

### 4. Discussion

This first review of our two-part study has its limitations, as it is meant to be a general overview of the current advances

---

**Table 2** A summary of key findings on the current knowledge of retinoblastoma.

| Finding | Summary |
|--------|---------|
| Retinoblastoma | is the most common primary malignancy in children, with a global incidence ranging from 36 to 67 per 1 million live births. |
| The International Classification for Intraocular Retinoblastoma | has been validated to accurately predict treatment outcomes and uses staging based on five groups (Groups A–E), with Group A representing more easily treated eyes with very low risk and Group E representing very high-risk eyes requiring the most complex therapy. |
| Early detection of retinoblastoma in Group A through C eyes | is essential for a timely referral to treat and potentially cure the patient without risking vision loss. |
| Ocular salvage and sight preservation | are the primary treatment outcomes following systemic chemotherapy of Group A–C and many Group D eyes. |
| External beam radiotherapy and enucleation | are indicated for Group D and Group E eyes, with enucleation necessary when sight preservation is unlikely and the tumor may spread to the optic nerve, choroid, or orbit. |
| Intra-arterial chemotherapy with melphalan/topotecan | is now a first-line treatment for Group C or D eyes. |
| Chemoresistant vitreous seeds | that form in tumor cells after they proliferate are the main barrier to successful conservative treatment of advanced retinoblastoma. |
| Intravitreal chemotherapy using melphalan and/or topotecan | is a therapeutic option for advanced tumors with vitreous seeds. However, higher doses of melphalan risk compromised retinal function, whereas up to 5 µg of topotecan is effective and shows minimal ocular toxicity. |
in Rb diagnosis and management. It by no means employs a rigorous or systematic methodology. Part 1 serves as the back drop and context of the current situation of Rb knowledge and programming in Mexico, which will be explored in Part 2.

The key findings for this review of recent literature on the general knowledge and advances of Rb diagnosis and management are summarized in Table 2. Today, provided there is early detection and referral of patients with Rb, this most commonly occurring pediatric cancer is curable. In developed countries, the primary treatment outcome is ocular salvage with sight preservation. Advanced chemotherapeutic options such as IAC and IVC can now save even the most advanced tumors.

Unfortunately, there are gaps in practice and skill in conservative management in lesser developed countries where Rb is often diagnosed after metastasis has occurred. In upper-middle income countries, large urban centers may have the latest technology and skilled highly specialized medical professionals, but these services are often not accessible to the population living outside these urban areas. This is the case in Argentina, an upper-middle income country where more prolific, advanced research on Rb has been done in recent years. Yet, children living outside of the capital city of Buenos Aires have a significantly higher risk of having Rb.

In Part 2 of this study, we will examine the literature related to Rb in another upper-middle income country, Mexico, and compare it to the general knowledge presented here in Part 1, analyze the state of Rb programming in the country, and report the patient data currently available at hospitals in Mexico that have formal Rb programs or treat patients with Rb.

Funding
Financing for the study was provided by the International Agency for the Prevention of Blindness/Orbis and the Hamilton Eye Institute of the University of Tennessee.

Conflicts of interest

VCL: paid employee of HelpMeSee, ad-honorem employee of the Instituto Mexicano de Oftalmología and the University of Tennessee, ex-employee of the International Agency for the Prevention of Blindness; KAE: independent consultant to International Agency for the Prevention of Blindness and Strategic Solutions, Inc; BGH: employed by University of Tennessee; BXP: employed by University of Tennessee; MARO: employed by Secretaría de Salud Pública (México); VBC: employed by Secretaría de Salud Pública (México).

References

1. Gallie BL, Campbell C, Devlin H, Duckett A, Squire JA. Developmental basis of retinal-specific induction of cancer by RB mutation. Cancer Res. 1999;59 Suppl 7:1731S-55.

2. Chintagumpala M, Chevez-Barrios P, Payse EA, Plon SE, Hurwitz R. Retinoblastoma: review of current management. Oncologist. 2007;12:1237-46.

3. Houston SK, Murray TG, Wolfe SQ, Fernandes CE. Current update on retinoblastoma. Int Ophthalmol Clin. 2011;51:77-91.

4. Devesa SS. The incidence of retinoblastoma. Am J Ophthalmol. 1975;80:263-5.

5. Chawla B, Jain A, Azad R. Conservative treatment modalities in retinoblastoma. Indian J Ophthalmol. 2013;61:479-85.

6. Usmanov RH, Kivelä T. Predicted trends in the incidence of retinoblastoma in the Asia-Pacific Region. Asia Pac J Ophthalmol (Phila). 2014;3:151-7.

7. Smith SJ, Smith BD. Evaluating the risk of extraocular tumour spread following intravitreal injection therapy for retinoblastoma: a systematic review. Br J Ophthalmol. 2013;97:1231-6. URL: http://bjo.bmj.com/content/early/2013/06/04/bjoophthalmol-2013-303188.full.html (accessed 23 January 2014).

8. Gunduz K, Kise K, Kurt RA, Süren E, Tacyildiz N, Dincaslan H, et al. Retinoblastoma in Turkey: results from a tertiary carecenter in Ankara. J Pediatr Ophthalmol Strabismus. 2013; 50:296-303.

9. Bowman RJ, Mafwiri M, Luthert P, Luande J, Wood M. Outcome of retinoblastoma in east Africa. Pediatr Blood Cancer. 2008; 50:160-2.

10. Kivelä T. The epidemiological challenge of the most frequent eye cancer: retinoblastoma, an issue of birth and death. Br J Ophthalmol. 2009;93:1129-31.

11. Leal-Leal C, Flores-Rojo M, Medina-Sansón A, Cerecedo-Díaz F, Sánchez-Félix S, González-Ramella O, et al. A multicentre report from the Mexican Retinoblastoma Group. Br J Ophthalmol. 2004;88:1074-7.

12. Wilimas JA, Wilson MW, Haik BG, Barnoya M, Fu L, Castellanos M, et al. Development of retinoblastoma programs in Central America. Pediatr Blood Cancer. 2009;53:42-6.

13. Howard S, Ortiz R, Baez LF, Cabanas R, Barrantes J, Fu L, et al. Meeting report: Protocol-based treatment for children with cancer in low income countries in Latin America: a report on the recent meetings of the Monza International School of Pediatric Hematology/Oncology (MISPHO)-PART II. Pediatr Blood Cancer. 2007;48:486-90.

14. Nair RM, Kalki S, Vemuganti GK. Animal models in retinoblastoma research. Saudi J Ophthalmol. 2013;27:141-6.

15. Rushlow DE, Mol BM, Kennett JY, Yee S, Pajovic S, Thériault BL, et al. Characterisation of retinoblastomas without RB1 mutations: genomic, gene expression, and clinical studies. Lancet Oncol. 2013;14:327-34.

16. Macias M, Dean M, Atkinson A, Jiménez-Morales S, García-Vázquez FJ, Saldaña-Álvarez Y, et al. Spectrum of RB1 gene mutations and loss of heterozygosity in Mexican patients with retinoblastoma: identifications of six novel mutations. Cancer Biomark. 2008;4:93-9.

17. Crosby MB, Hubbard GB, Gallie BL, Grossniklaus HE. Anterior diffuse retinoblastoma: mutational analysis and immunofluorescence staining. Arch Pathol Lab Med. 2009;133:1215-8.

18. Thériault BL, Dimaras H, Gallie BL, Corson TW. The genomic landscape of retinoblastoma: a review. Clin Exp Ophthalmol. 2014;42:33-52.

19. Chawla B, Khurana S, Sen S, Sharma S. Clinical misdiagnosis of retinoblastoma in Indian children. Br J Ophthalmol. 2014;98:488-93. Available from: http://bjo.bmj.com/content/early/2014/01/23/bjoophthalmol-2013-304321.full.html. (Accessed 27 January 2014).

20. Linn Murphree A. Intracocular retinoblastoma: the case for a new group classification. Ophthalmol Clin North Am. 2005;18:41-53.

21. Shields CL, Shields JA. Basic understanding of current classification and management of retinoblastoma. Curr Opin Ophthalmol. 2006;17:228-34.

22. Shields CL. The International Classification of Retinoblastoma is practical and predictable. In: Rapuano C, editor. Year Book of Ophthalmology. St Louis: Mosby; 2008. p. 227-30.
Retinoblastoma in Mexico: part I. A review of general knowledge of the disease

23. Chantada GL, Sampor C, Bosaleh A, Solernou V, Fandiño A, de Dávila MT. Comparison of staging systems for extraocular retinoblastoma: analysis of 533 patients. JAMA Ophthalmol. 2013;131:1127-34.

24. Lin P, O’Brien JM. Frontiers in the management of retinoblastoma. Am J Ophthalmol. 2009;148:192-8.

25. Shields CL, Santos MC, Diniz W, Gündüz K, Mercado G, Cater JR, et al. Thermotherapy for retinoblastoma. Arch Ophthalmol. 1999;117:885-93.

26. Abramson DH, Ellsworth RM, Rozakis GW. Cryotherapy for retinoblastoma. Arch Ophthalmol. 1982;100:1253-6.

27. Shields JA, Parsons H, Shields CL, Gobin YP. The role of cryotherapy in the management of retinoblastoma. Am J Ophthalmol. 1989;108:260-4.

28. Shields JA, Shields CL, Parsons H, Gobin YP. The role of photoocoagulation in the management of retinoblastoma. Arch Ophthalmol. 1990;108:205-8.

29. Shields JA. The expanding role of laser photoocoagulation for intraocular tumors. The 1993 H. Christian Zweng Memorial Lecture. Retina. 1994;14:310-22.

30. Shields CL, Jeang JD, Kiratli H, De Potter PV. Treatment of retinoblastoma with indirect ophthalmoscope laser photoocoagulation. J Pediatr Ophthalmol Strabismus. 1995;32:317-22.

31. Merchant TE, Gould CJ, Wilson MW, Hilton NE, Rodriguez-Galindo C, Haik BG. Episcleral plaque brachytherapy for retinoblastoma. Pediatr Blood Cancer. 2004;43:134-9.

32. Shields CL, Shields JA, De Potter P, Minelli S, Hernandez C, Brady LW, et al. Plaque radiotherapy in the management of retinoblastoma. Use as a primary and secondary treatment. Ophthalmology. 1993;100:216-24.

33. Hernandez JC, Brady LW, Shields CL, Shields JA, De Potter P. Conservative treatment of retinoblastoma. The use of plaque brachytherapy. Am J Clin Oncol. 1993;16:397-401.

34. Shields CL, Shields JA, Cater J, Othmane I, Singh AD, Micailly B. Plaque radiotherapy for retinoblastoma: long-term tumor control and treatment complications in 208 tumors. Ophthalmology. 2001;108:2116-21.

35. Mulvihill A, Budning A, Jay V, Vandenhoven C, Heon E, Gallie BL, et al. Ocular motility changes after subtenon carboptalin chemotherapy for retinoblastoma. Arch Ophthalmol. 2003;121:1120-4.

36. Schmack I, Hubbard GB, Kang SJ, Aaberg TM Jr, Grossniklaus HE. Ischemic necrosis and atrophy of the optic nerve after pericocular carboptalin injection for intraocular retinoblastoma. Am J Ophthalmol. 2006;142:310-5.

37. Kiratli H, Kocabeyoglu S, Bilgic, S. Severe pseudo-preseptal cellulitis following sub-Tenon’s carboptalin injection for intraocular retinoblastoma. J AAPOS. 2007;11:404-5.

38. Shields CL, Shields JA. Retinoblastoma management: advances in enucleation, intravenous chemoreduction, and intra-arterial chemotherapy. Curr Opin Ophthalmol. 2010;21:203-12.

39. Kaliki S, Shields CL, Rojanaporn D, Al-Dahmash S, McLaughlin JP, Shields JA, et al. High-risk retinoblastoma based on International Classification of Retinoblastoma: analysis of 519 enucleated eyes. Ophthalmology. 2013;120:997-1003.

40. Manjandavida FP, Honovar SG, Shields CL, Shields JA. Retinoblastoma: recent update and management frontiers (editorial). Asia-Pacific J Ophthalmol. 2013;2:351-3.

41. Shields CL, Fulco EM, Arias JD, Alarcon C, Pellegrini M, Rishi P, et al. Retinoblastoma frontiers with intra-ocular, intra-arterial, and intravitreal chemotherapy. Eye (Lond). 2012;27:253-64.

42. Ferris FL 3rd, Chew EY. A new era for the treatment of retinoblastoma. Arch Ophthalmol. 1996;114:1412.

43. Abramson DH, Dunkel IJ, Brodie SE, Kim JW, Gobin YP. A phase I/II study of direct intraarterial (ophthalmic artery) chemotherapy with melphalan for intraocular retinoblastoma initial results. Ophthalmology. 2008;115:1398-404.

44. Wilson MW, Haik BG, Billups CA, Rodriguez-Galindo C. Incidence of new tumor formation in patients with hereditary retinoblastoma treated with primary systemic chemotherapy: is there a preventive effect. Ophthalmology. 2007;114:2077-82.

45. Bartuma K, Pal N, Kosk S, Holm S, All-Ericsson C. A 10-year experience of outcome in chemotherapy-treated hereditary retinoblastoma. Acta Ophthalmol. 2014;92:404-11.

46. Kingston JE, Hungerford JL, Madreperla SA, Plowman PN. Results of combined chemotherapy and radiotherapy for advanced intraocular retinoblastoma. Arch Ophthalmol. 1996;114:1339-43.

47. Chantada GL, Qaddoumi I, Cantruk S, Khetan V, Ma Z, Kinani K, et al. Strategies to manage retinoblastoma in developing countries. Pediatr Blood Cancer. 2011;56:341-8.

48. Munier FL, Gaillard MC, Balmé A, Beck-Popovic M. Intra-venital chemotherapy for vitreous seeding in retinoblastoma. Recent advances and perspectives. Saudi J Ophthalmol. 2013;27:147-50.

49. Yamane T, Kaneko A, Mohri M. The technique of ophthalmic arterial infusion therapy for patients with intraocular retinoblastoma. Int J Clin Oncol. 2004;9:69-73.

50. Shields CL, Manjandavida FP, Arepalli S, Kaliki S, Lally SE, Shields JA. Intravitreal melphalan for persistent or recurrent retinoblastoma vitreous seeds: preliminary results. JAMA Ophthalmol. 2014;132:319-25.

51. Ghassemi F, Shields CL. Intravitreal melphalan for refractory or recurrent vitreous seeding from retinoblastoma. Arch Ophthalmol. 2012;130:1268-71.

52. Abramson DH, Dunkel IJ, Brodie SE, Marr B, Gobin YP. Superselective ophthalmic artery chemotherapy as primary treatment for retinoblastoma (chemosurgery). Ophthalmology. 2010;117:1623-9.

53. Shields CL, Shields JA. Intra-arterial chemotherapy for retinoblastoma: the beginning of a long journey. Clin Exp Ophthalmol. 2010;38:638-43.

54. Fernandes BF, Nikolitch K, Coates J, Novais G, Odashiro A, Odashiro PP, et al. Local chemotherapeutic agents for the treatment of ocular malignancies. Surv Ophthalmol. 2014;59:97-114.

55. Schaiquevich P, Buitrero E, Taich P, Torbidoni A, Cecilio A, Fandino A, et al. Pharmacokinetic analysis of melphalan after superselective ophthalmic artery infusion in preclinical models and retinoblastoma patients. Invest Ophthalmol Vis Sci. 2012;53:4205-12.

56. Taich P, Cecilio A, Buitrero E, Sampor C, Fandino A, Villasante F, et al. Clinical pharmacokinetics of intra-arterial melphalan and topotecan combination in patients with retinoblastoma. Ophthalmology. 2014;121:889-97.

57. Schaiquevich P, Cecilio A, Millan N, Taich P, Villasante F, Fandino AC, et al. Intra-arterial chemotherapy is more effective than sequential pericocular and intraocular chemotherapy as salvage treatment for relapsed retinoblastoma. Pediatr Blood Cancer. 2013;60:766-70.

58. Buitrero E, Höcht C, Chantada G, Fandiño A, Naveo E, Abramson DH, et al. Pharmacokinetic analysis of topotecan after intra-arterial injection, Implications for retinoblastoma treatment. Exp Eye Res. 2010;91:19-4.

59. Smith SJ, Smith BD, Mohnen BG. Ocular side effects following intra-arterial injection therapy for retinoblastoma: a systematic review. Br J Ophthalmol. 2014;98:292-7. URL: http://bjo.bmj. com/content/early/2013/11/01/bjophthalmol-2013-303885.full.html. (Accessed 24 January 2013).

60. Shields CL, Manjandavida FP, Lally SE, Piretti G, Arepalli SA, Caywood EH, et al. Intra-arterial chemotherapy for retinoblastoma in 70 eyes: outcomes based on the International Classification of Retinoblastoma. Ophthalmology. 2014;121:1453-60.
model: histopathologic findings. JAMA Ophthalmol. 2013;131:903-11.

62. Grossniklaus HE. Retinoblastoma. Fifty years of progress. The LXXI Edward Jackson Memorial Lecture. Am J Ophthalmol. 2014;158:875-91.

63. Manjandavida FP, Honavar SG, Reddy VAP, Khanna R. Management and outcome of retinoblastoma with vitreous seeds. Ophthalmology. 2014;121:517-24.

64. Francis JH, Schaiquevich P, Buitrago E, Del Sole MJ, Zapata G, Croxatto JO, et al. Local and systemic toxicity of intravitreal melphalan for vitreous seeding in retinoblastoma: a preclinical and clinical study. Ophthalmology. 2014;121:1810-7.

65. Munier FL, Gaillard MC, Balmer A, Soliman S, Podlisky G, Moulin AP, et al. Intravitreal chemotherapy for vitreous disease in retinoblastoma revisited: from prohibition to conditional indications. Br J Ophthalmol. 2012;96:1078-83.

66. Buitrago E, Del Sole MJ, Torbidoni A, Fandino A, Asprea M, Croxatto JO, et al. Ocular and systemic toxicity of intravitreal topotecan in rabbits for potential treatment of retinoblastoma. Exp Eye Res. 2013;108:103-9.

67. Schaiquevich P, Carcaboso AM, Buitrago E, Taich P, Opezzo J, Bramuglia G, et al. Ocular pharmacology of topotecan and its activity in retinoblastoma. Retina. 2014;34:1719-27.

68. Winter U, Buitrago E, Mena HA, Del Sole MJ, Laurent V, Negrotto S, et al. Pharmacokinetics, safety, and efficacy of intravitreal digoxin in preclinical models for retinoblastoma. Invest Ophthalmol Vis Sci. 2015;56:4382-93.

69. Chantada G, Luna-Fineman S, Sitorus RS, Kruger M, Israels T, Leal-Leal C, et al. On behalf of the SIOP-PODC Graduated-Intensity Retinoblastoma Guidelines Writing Committee. SIOP-PODC recommendations for graduated-intensity treatment of retinoblastoma in developing countries. Pediatr Blood Cancer. 2013;60:719-27.

70. Chantada G. Retinoblastoma: lessons and challenges from developing countries. Ellsworth Lecture 2011. Ophthalmic Genet. 2011;32:196-203.

71. Chantada G, Fandiño A, Manzitti J, Urrutia L, Schwartzman E. Late diagnosis of retinoblastoma in a developing country. Arch Dis Child. 1999;80:171-4.